Corneal neovascularization reduced with short-term topical anti-VEGF

Short-term topical bevacizumab may reduce corneal neovascularization, according to a study.The prospective, nonrandomized trial included 20 eyes of 20 patients with stable corneal neovascularization. All patients received topical 1% Avastin (bevacizumab, Genentech) two or four times daily for 3 weeks; patients were monitored for 24 weeks.